Sirtris Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference January 7, 2008
January 03 2008 - 7:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that it will be presenting at the 26th Annual JPMorgan Healthcare
Conference on Monday January 7, 2008 at 1:30 pm PST in San
Francisco. Sirtris will discuss the Company�s strategy for
discovering and developing first-in-class therapeutics that
modulate sirtuins, a recently discovered class of enzymes that
control the aging process, as well as the Company�s clinical
progress. The presentation will be webcast live and can be accessed
on the Sirtris website, www.sirtrispharma.com, in the investor
relations section. A replay will be available approximately
twenty-four hours after the presentation and will be archived on
the Company�s website for two weeks. About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators for diseases of aging, the progress and results
of pre-clinical and clinical studies of SIRT1 activators,
development of first-in-class therapeutics that modulate sirtuins,
and the potential of sirtuin modulators to receive regulatory
approval. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the�Company to gain market acceptance of the Company's
product candidates, and those other risks factors�that can be found
in the�Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles